Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by David Shyr
JCM | Free Full-Text | Exploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Exploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 15 May 2024 / Approved: 16 May 2024 / Online: 16 May 2024 (17:18:14 CEST) Shyr, D.; Zhang, B.; Saini, G.; Brewer, S. Exploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods. Preprints 2024, 2024051116. https://doi.org/10.20944/preprints202405.1116.v1 Shyr, D.; Zhang, B.; Saini, G.; Brewer, S.
David Shyr, MD, on Incorporating AI Into Medicine
“Sometimes big data is not available, especially for pediatric doctors who deal with rare diseases, small patient populations. I would love to have thousands of cases, but there are thousands of cases. So how do you overcome that? I think that is where machine learning can come in. Artificial intelligence offers a tool to tackle problems we were previously not able to solve or would need to be solved with in multicenter international collaborations to gain the power needed.
David Shyr, MD, on ASH 2023 Highlights, Further Research for Nula-Cel SCD Therapy
“This is the first step right now, the patient who needs a cure, who transplant is not indicated ,but has another option. Could this option replace transplant? I think so. I think that's the future, that you don't need to do allogeneic transplant for this disease anymore. We can do gene therapy.
David Shyr, MD, on Surprising Findings With CRISPR Cell Therapy Nula-Cel in Sickle Cell Disease
“When she recovered, she was making mostly hemoglobin F, which was a surprise to us because our gene therapy does not alter hemoglobin F in any way. So, we're happy to report 1 year out. She has a stable hemoglobin around 10-11, a good healthy platelet count near 100, normal white blood cell count, normal neutrophil count, and she has only 3% hemoglobin S, and mostly hemoglobin F. And she's feeling great. No more pain crisis.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with David
Contact David, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack